LISCure Biosciences
- Biotech or pharma, therapeutic R&D
LISCure is building a pipeline of novel and best-in-class biotherapeutics targeting hard-to-treat medical conditions. R&D pipeline includes clinical assets in liver disease and autoimmune disease and preclinical assets in neurology and oncology. LISCure is developing an exosome-mediated BBB shuttle platform which has proven to be highly efficient in loading and delivering therapeutic cargos across the BBB.
◈ LB-P8: Seeking partnership opportunity for late stage development and commercialization of our Phase 2 asset targeting Primary Sclerosing Cholangitis (a rare and chronic liver disease)
◈ Exo-PN (LB-P4E): Seeking research collaboration partners and strategic alliances for our BBB shuttle platform which demonstrates superior brain penetration rate, cargo loading and knockdown efficiency, as well as functional delivery of various types of cargo
◈ Capital Raise: Currently at post-Series C and open to bridge funding to accelerate advancement of preclinical assets into the clinic
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}